Should I buy, hold, or sell PAHC stock right now?

Phibro Animal Health Corporation (Class A) (PAHC) currently earns a Roarable Rating of D+ (Sell — SELL) with 56/100 RQD Confidence. Stretched risk/reward at 33x P/E (10% return on capital) under elevated 10-year interest-rate pressure.

What is PAHC's 12-month price target and RQD AI Jury consensus?

PAHC's 12-month base price target is $38.39 (range $29.94 to $63.08), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Stock Ratings / Health Care / PAHC

RARE (23) NBTX (49) GPCR (27) URGN (24) ⌘ Pro Terminal →

Phibro Animal Health Corporation (Class A) (PAHC) — RQD Stock Rating Cockpit

$38.74 -0.36% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $38.64

Phibro Animal Health Corporation (Class A) (PAHC) carries a Roarable Rating of D+ (Sell) with 56/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $1.58B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PAHC Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PAHC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Phibro Animal Health Corporation (Class A) (NASDAQ: PAHC) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $38.74 (-0.36% 1D, market cap $1.58B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 14/20. Across 1015 tracked Health Care issuers, PAHC ranks #197 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PAHC compare to RARE and NBTX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PAHC carries a Roarable D+ (56/100 RQD), trailing P/E of 32.7x, gross margin of 30.9%, and ROIC of 9.9%. By comparison, RARE (Ultragenyx Pharmaceutical Inc.) holds a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $1.59B) and NBTX (Nanobiotix S.A.) posts a D grade (49/100 RQD, P/E N/A, ROIC —, cap $1.59B). Among the 5-stock peer group, PAHC leads on earnings multiple (32.7x) while PAHC leads on capital efficiency (9.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PAHC?

▼

Per PAHC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001069899), Phibro Animal Health Corporation (Class A) generated $1.30B in revenue (+27.4% YoY), $48.3M in net income, and $80.1M in free cash flow against $1.41B in total assets and $603.6M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $38.64 (-0.25%)🧬 Cannibal Buyback (-1.80% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 6.2% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 56/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.4% avg 90D alpha vs SPY • 51.8% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-0.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PAHC)Realized 20D OHLCV Swing Band: ±7.1%

Deterministic 5-Pillar Attribution (56/100 Composite)

🔍 WHY PAHC SCORES 56/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (25% of score)

Altman Z-Score 2.87 (WATCH ZONE (1.8–3.0)) • Piotroski F-Score 8/9

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+14/20 pts (25% of score)

SEC Form 4 / 13F Thermometer: 70% Net Buy • Cannibal Buyback (-1.80% YoY Shares)

▼ #1 Drag / Risk Factor: Macro Regime Fit7/20 pts (-13 pt drag)

Macro rate sensitivity & RSI-14 (56.9) create a -13 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$36.81+5.4% Next Q

Q2 (-2Q)

Grade C-$38.80-1.1% Next Q

Q3 (-1Q)

Grade C-$38.38+0.9% Next Q

Current

Grade D+$38.74-0.4% Hist 90D α

Trajectory: D (48) → D+ (56)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the PAHC Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 56/100 (D+) score, PAHC faces multiple-compression risk if 32.7x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.80% YoY Shares) — any gross margin slip below 28.4% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($37.12) or 200D SMA ($41.25) invalidates the momentum regime and cuts Target Base ($38.39) toward Bear Floor ($29.94).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PAHC• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PAHC Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”

YES 56%NO 44%Trade / Inspect Odds →

RSI-14 MOMENTUMBULLISH MOMENTUM

56.930 Oversold · 70 Hot

ALTMAN-Z SHIELDWATCH ZONE (1.8–3.0)

2.87>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

8 / 99-Pt Accounting

52-WEEK LASER RANGE33% OF RANGE

L: $28$38.74H: $60

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (30.9% gross margin), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20

2. Big Money & Insiders● NEUTRAL

Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: D+RQD 23 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D+RQD 21 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on PAHC

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

NEUTRAL (60)

9.9% ROIC with 30.9% gross margin and 5.08% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (70)

Altman-Z 2.87 and Piotroski 8/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (50)

23/40 institutional & smart-money positioning score with 7/20 macro alignment.

Bull Case: Why Buyers Like PAHC

✓Company leadership has skin in the game with net positive insider conviction.

Bear Case: What Could Go Wrong

!Sensitive to high interest rates and tighter Federal Reserve market liquidity.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PAHC)

✓Walkthrough of PAHC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PAHC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -29.15%⚡ TESTING RESISTANCE

2026-11-03O $38.86H $38.88L $38.74C $38.74VOL 182.8K

RES: $40.92SUP: $34.17SMA50: $37.12SMA200: $41.25

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PAHC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PAHC Butterfly Map → + Track PAHC →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

25.3%/yr Implied 5Y Growth

vs. +27.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PAHC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PAHC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PAHC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PAHC)

Health Care Rank #197 of 1015 ⚔️ RARE vs PAHC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PAHC vs. RARE, NBTX, GPCR, URGN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Phibro Animal Health Corporation (Class A) (PAHC) ranks #197 by composite RQD confidence (56/100, grade D+) and #294 by equity capitalization ($1.58B). Within this direct 5-issuer industry benchmark cohort, PAHC leads on earnings valuation at 32.7x trailing P/E, while PAHC leads on capital efficiency and profitability with 9.9% ROIC and 30.9% gross margin. PAHC currently leads its immediate peer cohort in composite quantitative strength at 56/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PAHC ACTIVE Phibro Animal Health Corporation (Class A)	D+	56/100	32.7x	30.9%	9.9%	-0.36%	$1.58B	Benchmark Subject
RARE Ultragenyx Pharmaceutical Inc.	E	23/100	—	—	-35.0%	+1.24%	$1.59B	/rare-vs-pahc →
NBTX Nanobiotix S.A.	D	49/100	—	—	—	-10.39%	$1.59B	/nbtx-vs-pahc →
GPCR Structure Therapeutics Inc.	E	27/100	—	—	-19.5%	-6.40%	$1.56B	/gpcr-vs-pahc →
URGN UroGen Pharma Ltd.	E	24/100	—	88.7%	-35.0%	+5.01%	$1.60B	/urgn-vs-pahc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001069899 ↗

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Phibro Animal Health Corporation (Class A) (PAHC) reported GAAP revenue of $1.30B (+27.4% vs. FY2024 revenue of $1.02B , and +32.6% cumulative change since FY2023) , GAAP net income of $48.3M, operating cash flow of $80.1M, and free cash flow of $80.1M (-8.5% YoY). On the balance sheet, PAHC closed FY2025 with $1.41B in total assets against $603.6M in total debt (Altman Z-Score: 2.87, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-06-30	$1.30B	$48.3M	$80.1M	$80.1M	$1.41B	$603.6M
FY2024 (FY)	2024-06-30	$1.02B	$2.4M	$87.6M	$87.6M	$1.29B	$622.9M
FY2023 (FY)	2023-06-30	$977.9M	$32.6M	$13.3M	$13.3M	—	—

3. PAHC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PAHC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PAHC compare to RARE and NBTX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for PAHC?

Where is PAHC trading relative to its 50-day, 200-day, and 52-week technical levels?

PAHC last traded at $38.74 (-0.36% on volume of 250,474 shares), positioning the stock +4.36% above its 50-day simple moving average ($37.12) and -6.08% below its 200-day simple moving average ($41.25). Across its 52-week range of $28.25 to $60.08, PAHC sits at the 33.0% percentile with a 14-day RSI of 56.9 (BULLISH MOMENTUM) and an implied next-earnings move of ±7.1% ($35.99 to $41.49).

Direct Sub-Reports: PAHC RQD Cockpit PAHC 12M Forecast PAHC Earnings & Move PAHC Dividends & DRIP PAHC Insiders & 13F PAHC Whale Options PAHC Profit Sankey PAHC News & Why

ROARABLE RATING BRIEF • RQD 56/100 (D+) ✓ SEC XBRL & RQD VERIFIED

PAHC — Phibro Animal Health Corporation (Class A): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-06-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

Phibro Animal Health Corporation (Class A) (PAHC) earns a live Roarable RQD composite score of 56/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $38.74 (-0.36% 1D, market capitalization $1.58B).

Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of 9.9%, gross margin of 30.9%, operating margin of 8.5%, and free cash flow yield of 5.08%.
Whale 13F & Options Flow (9/20) + Insider Conviction (14/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (7/20) + Forensic Balance Sheet (14/20): Incorporates a 1.00x equity beta, Altman Z-Score of 2.87, Piotroski F-Score of 8/9, and Debt/Equity of 1.82x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Phibro Animal Health Corporation (Class A) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..6B. Reported FY 2025 revenue was $1.30B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-06-30), Phibro Animal Health Corporation (Class A) (PAHC) reported $1.30B in annual revenue (up from $1.02B in FY2024, +27.4% YoY) and $48.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($977.9M revenue, $32.6M net income) through FY2025, PAHC scaled operating cash flow to $80.1M and free cash flow to $80.1M, backed by $1.41B in total assets against $603.6M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D+ • RQD 56/100): Company leadership has skin in the game with net positive insider conviction. Free cash flow yield of 5.08% and institutional whale pillar of 9/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $28.25 – $60.08 52-week range.
🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh 32.7x trailing P/E and 19.2x EV/EBITDA against 8.5% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The sector and industry classification (Health Care; Biotechnology: Pharmaceutical Preparations) is the only contextual anchor provided. Second-order bottlenecks cannot be identified from the supplied material.

Key Question #1: Can PAHC sustain or expand its 8.5% operating margin and 9.9% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $1.30B and free cash flow of $80.1M, how will capital allocation balance growth reinvestment against $603.6M in total debt?
Key Question #3: How sensitive is PAHC's 27.5x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PAHC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Phibro Animal Health Corporation (Class A) (PAHC) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PAHC Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 1d ago

What Is Drawing Attention To Phibro Animal Health (PAHC) Today?

Yahoo Finance report covering Phibro Animal Health Corporation (Class A) (PAHC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Should Value Investors Buy Phibro Animal Health (PAHC) Stock?

Yahoo Finance report covering Phibro Animal Health Corporation (Class A) (PAHC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Phibro Animal Health Corporation Estimates – NASDAQ:PAHC

TradingView report covering Phibro Animal Health Corporation (Class A) (PAHC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Phibro Animal Health (NasdaqGM:PAHC) Stock Forecast & Analyst Predictions

Simply Wall St report covering Phibro Animal Health Corporation (Class A) (PAHC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Phibro Animal Health Corporation to Host Webcast and Conference Call on First Quarter Results

Yahoo Finance report covering Phibro Animal Health Corporation (Class A) (PAHC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Is it Apt to Retain Prestige Consumer Stock in Your Portfolio Now?

TradingView report covering Phibro Animal Health Corporation (Class A) (PAHC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

PAHC vs. HAE: Which Stock Is the Better Value Option?

Yahoo Finance report covering Phibro Animal Health Corporation (Class A) (PAHC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

PAHC or SYK: Which Is the Better Value Stock Right Now?

Yahoo Finance report covering Phibro Animal Health Corporation (Class A) (PAHC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PAHC Bull vs. Bear Conversation Board — What's Your Call at $38.74?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PAHC 🐻 33% BEARISH CONVICTION

DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $46.66 (+20.0%)

📌 Pinned Debate

Per the SEC financials, net income rose from $2.4M in FY 2024 to $48.3M in FY 2025 while operating income climbed to $110.5M, and the P

Long PAHC at $38.88 targeting $46.66. Per the SEC financials, net income rose from $2.4M in FY 2024 to $48.3M in FY 2025 while operating income climbed to $110.5M, and the Piotroski F-Score of 8/9 indicates strong forensic health.. Institutional whale score is 9/20 and the risk/reward vs. the $28.25 52-week low is skewed heavily in favor of bulls.

SectorRotator 🐂 BULL

@DeltaGamma_99 Agree on the RQD 56/100 quality, though with 1.0 beta I'm scaling in with half-size at $38.88 and keeping dry powder in case we test $36.16.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $30.72 (-21.0%)

Spot @ $38.88

Per the Roarable RQD rating, macro regime fit scores only 7 of 20 at beta 1.0, Debt/Equity is 1.82, and the rating's verdict is Roarabl

Fading this rally in PAHC at $38.88. Per the Roarable RQD rating, macro regime fit scores only 7 of 20 at beta 1.0, Debt/Equity is 1.82, and the rating's verdict is Roarable Sell — Weak Fundamentals / Trim.. With a beta of 1.0 and the stock sitting at $38.88 (52-wk range $28.25–$60.08), the easy multiple expansion is already priced in.